Startseite/Aktien/AUTL

AUTL

USD

Autolus Therapeutics plc American Depositary Share

$1.410-0.110 (-7.237%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigtes Königreich

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.520

Hoch

$1.535

Tief

$1.400

Volumen

2.28M

Unternehmensfundamentaldaten

Marktkapitalisierung

375.3M

Branche

Biotechnologie

Land

United Kingdom

Handelsstatistiken

Durchschnittliches Volumen

3.73M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $1.105Aktuell $1.410Hoch $4.12

Ähnliche Nachrichten

3. Nov. 2025 · 17:14

Analyst Upgrades

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $10 price target.

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

3. Nov. 2025 · 14:05

GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

27. Okt. 2025 · 11:00

GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal